Lawrence F. Eichenfield

1997–2025 年に発表

別表記
Lawrence F Eichenfield
171
論文数
20,547
被引用数
81
h 指数
152
i10 指数

被引用数

Lawrence F. Eichenfield の年別被引用数1962 年: 被引用 1 件1980 年: 被引用 1 件1986 年: 被引用 1 件1999 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 7 件2002 年: 被引用 14 件2003 年: 被引用 26 件2004 年: 被引用 44 件2005 年: 被引用 46 件2006 年: 被引用 22 件2007 年: 被引用 34 件2008 年: 被引用 51 件2009 年: 被引用 41 件2010 年: 被引用 36 件2011 年: 被引用 50 件2012 年: 被引用 75 件2013 年: 被引用 75 件2014 年: 被引用 72 件2015 年: 被引用 78 件2016 年: 被引用 123 件2017 年: 被引用 152 件2018 年: 被引用 151 件2019 年: 被引用 649 件2020 年: 被引用 641 件2021 年: 被引用 774 件2022 年: 被引用 640 件2023 年: 被引用 602 件2024 年: 被引用 927 件2025 年: 被引用 552 件2026 年: 被引用 4 件1963〜1979 年は被引用が無いため表示していません1981〜1985 年は被引用が無いため表示していません1987〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 1,928 件、この内訳の 23.8%ドイツ: 引用元論文 566 件、この内訳の 7%イギリス: 引用元論文 534 件、この内訳の 6.6%中国: 引用元論文 408 件、この内訳の 5.1%イタリア: 引用元論文 408 件、この内訳の 5%カナダ: 引用元論文 393 件、この内訳の 4.9%フランス: 引用元論文 307 件、この内訳の 3.8%日本: 引用元論文 300 件、この内訳の 3.7%スペイン: 引用元論文 251 件、この内訳の 3.1%オランダ: 引用元論文 240 件、この内訳の 3%デンマーク: 引用元論文 220 件、この内訳の 2.7%スイス: 引用元論文 217 件、この内訳の 2.7%
0%23.8%その他 28.6%

分野

  • Medicine80%
  • Biochemistry, Genetics and Molecular Biology7.7%
  • Immunology and Microbiology6.2%
  • Neuroscience1.9%
  • Pharmacology, Toxicology and Pharmaceutics1%
  • Health Professions0.8%
  • その他2.4%

トピック

  • Dermatology and Skin Diseases17.9%
  • Allergic Rhinitis and Sensitization10.4%
  • Food Allergy and Anaphylaxis Research8.4%
  • Asthma and respiratory diseases6.6%
  • Psoriasis: Treatment and Pathogenesis6%
  • Urticaria and Related Conditions2.5%
  • その他48.2%

共著者

全論文

検索で開く
  1. Management of Acne Vulgaris

    著者: , , - JAMA 2021 被引用: 361

  2. Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Allergy and Clinical Immunology 2010 被引用: 2,342

  3. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies

    著者: , , , , , , , , , , - Journal of the American Academy of Dermatology 2021 被引用: 297

  4. Guidelines of care for the management of atopic dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2013 被引用: 1,257

  5. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies

    著者: , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2023 被引用: 215

  6. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis

    著者: , , , , , , , - JAMA Dermatology 2020 被引用: 339

  7. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults

    著者: , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2016 被引用: 565

  8. Guidelines of care for the management of atopic dermatitis in adults with topical therapies

    著者: , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2023 被引用: 182

  9. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis

    著者: , , , , , , , , , , , , , , , - JAMA Dermatology 2020 被引用: 279

  10. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials

    著者: , , , , , , , , , , , , , , , , , , , , , , , - British Journal of Dermatology 2020 被引用: 379

  11. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Molecular Psychiatry 2016 被引用: 503

  12. American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults

    著者: , , , , , , , , , , , - Journal of the American Academy of Dermatology 2022 被引用: 152

  13. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS)

    著者: , , , , , , , , , - British Journal of Dermatology 2023 被引用: 86

  14. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies

    著者: , , , , , , , , , , - Journal of the American Academy of Dermatology 2022 被引用: 92

  15. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)

    著者: , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2018 被引用: 329

  16. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders

    著者: , , , , , , , , , , , - American Journal of Clinical Dermatology 2018 被引用: 267

  17. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis

    著者: , , , , , , , , , , , , , , - JAMA Dermatology 2021 被引用: 162

  18. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2017 被引用: 236

  19. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials

    著者: , , , , , , , , , , , , , , , - Journal of the American Academy of Dermatology 2024 被引用: 86

  20. The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian J. Nickoloff, Yves Dutronc, Lotus Mallbris, Jonathan Janes, Amy M. DeLozier, Fabio P. Nunes, Amy S. Paller - Journal of the American Academy of Dermatology 2020 被引用: 178

  21. Recent Developments and Advances in Atopic Dermatitis: A Focus on Epidemiology, Pathophysiology, and Treatment in the Pediatric Setting

    著者: , , , , , - Pediatric Drugs 2022 被引用: 104

  22. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

    著者: , , , , , , , , , , , , , , - Dermatology and Therapy 2023 被引用: 44

  23. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies

    著者: , , , , , , , , , , - The Journal of Allergy and Clinical Immunology In Practice 2017 被引用: 192

  24. Atopic dermatitis: pathogenesis

    著者: , , , , - Seminars in Cutaneous Medicine and Surgery 2017 被引用: 103